Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.64 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178705 | 1.00 | CES2 (0.64) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL4865398 | 1.00 | CES2 (0.64) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL4860910 | 1.00 | CES2 (0.64) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL4856778 | 0.97 | CES2 (0.60) | CES2CES1TSHRGPR84ALDH1A1 | |
| SCHEMBL5936351 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL9057797 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL9054385 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL3939399 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL9465217 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA | |
| SCHEMBL11784529 | 0.91 | CES2 (0.59) | CES2CES1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452551-B1 | Targeted compositions for diagnostic and therapeutic use | IMARX THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7329402-B2 | Methods of imaging and treatment | IMARX PHARMACEUTICAL CORP. (US) | 2008-02-12 | — | — | US | disclosed |
| CN-1727008-A | Gas bearing activator of dry powder in use for diagnosing and/or treating thrombus | UNIV XI AN JIAOTONG (CN) | 2006-02-01 | — | — | CN | disclosed |
| EP-1365805-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | Imarx Therapeutics, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030157025-A1 | Novel methods of imaging and treatment with targeted compositions | UNGER EVAN C (US) | 2003-08-21 | — | — | US | disclosed |
| US-6521211-B1 | Administering gases and ligand mixtures encapsulated in vesicles, scanning with ultrasonic frequency to oscillateand collapse the micelles, then detecting the reflected signals; medical diagnosis | BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. | 2003-02-18 | — | — | US | disclosed |
| WO-2002036161-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1146911-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000045856-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157025-A1 | Novel methods of imaging and treatment with targeted compositions | FABP3, PLAUR, ASGR1 | CES2 4467/4885CES1 3662/4885PPARG 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.